Therapeutic efficacy of chloroquine plus primaquine in the treatment of uncomplicated P.vivax in Shecha Health Center, South Ethiopia.
- 1Department of Clinical Pharmacy, School of Pharmacy, Institute of Health Sciences, Wollega University, Nekemte, Ethiopia.
- 2Bacterial, Parasitic and Zoonotic Diseases, Ethiopian Public Health Institute, Addis Ababa, Ethiopia.
Abstract
Malaria is one of vector-borne diseases caused by plasmodium species. Plasmodium falciparum and Plasmodium vivax have a higher prevalence in Ethiopia. To combat this illness, effective therapy is necessary. Chloroquine plus radical cure with 14 days primaquine is a first-line antimalarial treatment for P.vivax. However, malaria treatment in Ethiopia is significantly impeded by resistance. The purpose of this study was to determine the therapeutic efficacy of chloroquine with radical cure with 14 days of primaquine in the treatment of uncomplicated P. vivax in Shecha Health Center, South Ethiopia. A single-arm, prospective therapeutic efficacy trial was conducted from December 2022 to March 2023 at Shecha Health Center in south Ethiopia. The study subjects were chosen using the purposive sampling technique. The study patients were given a 25 mg/kg standard dosage of chloroquine for three days and a 0.25 mg/kg standard dose of Primaquine for fourteen days. The World Health Organization double-entry Excel sheet was utilized for Kaplan-Meier survival analysis, and the laboratory and clinical data were analyzed using the Statistical Package for Social Sciences version-26 software. P-values less than 0.05 were considered statistically significant. The study endpoint was adequate clinical and parasitological response on day 42. Out of the 100 study participants, 90 (90.0%) completed the 42-day follow-up period. Male research participants make 57 (57%) of the total. Adults made up the majority of the study subjects 60 (60.0%). The adequate clinical and parasitological response rate was 96.7% (95% CI: 90.1-98.9%). On day three, parasitemia was cleared at 80 (82.5%) and fever at 95 (97.9%). There were no serious adverse reactions reported. Chloroquine plus primaquine is still an effective drug therapy for uncomplicated P.vivax, with rapid clearance of parasitemia, fever, improvement of hemoglobin, and clinical resolution. Therefore, chloroquine plus primaquine should continue as a first-line drug to treat uncomplicated P.vivax malaria in the study area.
Related
- Comparing malaria transmission blocking efficacy of Primaquine and Tafenoquine with in vivo pre-clinical models
- The SCOUT agree: nitrofurantoin is safe and effective for first-line treatment of uncomplicated lower urinary tract infections in women.
- Subgroup Analysis of Pooled Phase 3 Efficacy Data From Two Randomized Trials of Gepotidacin Versus Nitrofurantoin in Uncomplicated Urinary Tract Infections (EAGLE-2 and EAGLE-3) Including Participants With Uropathogens Not-Susceptible to Nitrofurantoin
- Endoscopic pilonidal sinus treatment versus Limberg flap reconstruction for uncomplicated pilonidal sinus disease: a prospective comparative study
- Time to recovery and its predictors among children aged 6 to 59 months with uncomplicated severe acute malnutrition treated in outpatient therapeutic programs in Adet Woreda, Central Zone of Tigray, Northern Ethiopia: A retrospective cohort study
BibTeX
@article{dugassa2026therapeutic,
title = {{Therapeutic efficacy of chloroquine plus primaquine in the treatment of uncomplicated P.vivax in Shecha Health Center, South Ethiopia.}},
author = {Dinka Dugassa and Busha Gamachu and Hussein Mohammed and Yonas Wuletaw and Geremew Tasew and Getachew Tollera and Mesay Hailu and Moges Kassa and Bokretsion G Brhane},
journal = {Parasite epidemiology and control},
year = {2026},
month = oct,
doi = {10.1016/j.parepi.2026.e00554},
url = {https://europepmc.org/article/MED/42999481},
note = {CC BY},
}
RIS
TY - JOUR
TI - Therapeutic efficacy of chloroquine plus primaquine in the treatment of uncomplicated P.vivax in Shecha Health Center, South Ethiopia.
AU - Dinka Dugassa
AU - Busha Gamachu
AU - Hussein Mohammed
AU - Yonas Wuletaw
AU - Geremew Tasew
AU - Getachew Tollera
AU - Mesay Hailu
AU - Moges Kassa
AU - Bokretsion G Brhane
PY - 2026
DA - 2026/10/08
JO - Parasite epidemiology and control
DO - 10.1016/j.parepi.2026.e00554
UR - https://europepmc.org/article/MED/42999481
AB - Malaria is one of vector-borne diseases caused by plasmodium species. Plasmodium falciparum and Plasmodium vivax have a higher prevalence in Ethiopia. To combat this illness, effective therapy is necessary. Chloroquine plus radical cure with 14 days primaquine is a first-line antimalarial treatment for P.vivax. However, malaria treatment in Ethiopia is significantly impeded by resistance. The purpose of this study was to determine the therapeutic efficacy of chloroquine with radical cure with 14 days of primaquine in the treatment of uncomplicated P. vivax in Shecha Health Center, South Ethiopia. A single-arm, prospective therapeutic efficacy trial was conducted from December 2022 to March 2023 at Shecha Health Center in south Ethiopia. The study subjects were chosen using the purposive sampling technique. The study patients were given a 25 mg/kg standard dosage of chloroquine for three days and a 0.25 mg/kg standard dose of Primaquine for fourteen days. The World Health Organization double-entry Excel sheet was utilized for Kaplan-Meier survival analysis, and the laboratory and clinical data were analyzed using the Statistical Package for Social Sciences version-26 software. P-values less than 0.05 were considered statistically significant. The study endpoint was adequate clinical and parasitological response on day 42. Out of the 100 study participants, 90 (90.0%) completed the 42-day follow-up period. Male research participants make 57 (57%) of the total. Adults made up the majority of the study subjects 60 (60.0%). The adequate clinical and parasitological response rate was 96.7% (95% CI: 90.1-98.9%). On day three, parasitemia was cleared at 80 (82.5%) and fever at 95 (97.9%). There were no serious adverse reactions reported. Chloroquine plus primaquine is still an effective drug therapy for uncomplicated P.vivax, with rapid clearance of parasitemia, fever, improvement of hemoglobin, and clinical resolution. Therefore, chloroquine plus primaquine should continue as a first-line drug to treat uncomplicated P.vivax malaria in the study area.
SN - 2405-6731
ER -